EUVIMEDEUVIMED entdecken
Crossref

Canagliflozin: SGLT2 inhibitor for treating type 2 diabetes

Richard Donnelly

Future Prescriber · 2013

DOI: 10.1002/fps.101 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Prescriber, 2013. Verfasst von Richard Donnelly. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Canagliflozin is a sodium‐glucose transporter protein inhibitor under development for the treatment of type 2 diabetes mellitus; it reduces circulatory glucose by facilitating its urinary excretion. In this Drug profile, Richard Donnelly discusses the need for drugs with a mode of action independent of insulin and considers the efficacy and tolerability of canagliflozin in clinical trials, to date, as well as its potential place in management. Copyright © 2013 John Wiley & Sons, Ltd.

Zitieren

APA

Donnelly, R. (2013). Canagliflozin: SGLT2 inhibitor for treating type 2 diabetes. Future Prescriber. https://doi.org/10.1002/fps.101

Vancouver

Donnelly R. Canagliflozin: SGLT2 inhibitor for treating type 2 diabetes. Future Prescriber. 2013. doi:10.1002/fps.101

BibTeX
@article{Donnelly2013,
  author = {Donnelly, Richard},
  title = {Canagliflozin: SGLT2 inhibitor for treating type 2 diabetes},
  journal = {Future Prescriber},
  year = {2013},
  doi = {10.1002/fps.101}
}
Kostenlos starten →